Molecular deep surgical margin analysis has been shown to predict locoregional recurrences of head and neck squamous cell carcinoma (HNSCC). In order to improve the accuracy and versatility of the analysis, we used a highly tumor-specific methylation marker and highly sensitive detection technology to test DNA from surgical margins. Histologically cancer-negative deep surgical margin samples were prospectively collected from 82 eligible HNSCC surgeries by an imprinting procedure (n=75) and primary tissue collection (n=70). Bisulfite treated DNA from each sample was analyzed by both conventional quantitative methylation-specific polymerase chain reaction (QMSP) and QMSP by droplet digital PCR (ddQMSP) targeting PAX5 gene promoter methylation. The association between the presence of PAX5 methylation and locoregional recurrence free survival (LRFS) was evaluated. PAX5 methylation was found in 68.0% (51/75) of tumors in the imprint samples and 71.4% (50/70) in the primary tissue samples. Among cases which did not have postoperative radiation, (n=31 in imprint samples, n=29 in tissue samples), both conventional QMSP and ddQMSP revealed that PAX5 methylation positive margins was significantly associated with poor LRFS by univariate analysis. In particular, ddQMSP increased detection of the PAX5 marker from 29% to 71% in the non-radiated imprint cases. Also, PAX5 methylated imprint margins were an excellent predictor of poor LRFS (HR=3.89, 95%CI:1.19-17.52, P=0.023) by multivariate analysis. PAX5 methylation appears to be an excellent tumor-specific marker for molecular deep surgical margin analysis of HNSCC. Moreover, the ddQMSP assay displays increased sensitivity for methylation marker detection.